Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Klinická studie injekce BAT4406F u pacientů s neuromyelitidou a poruchami optického spektra

29. září 2026 aktualizováno: Bio-Thera Solutions

Studie fáze II/III k vyhodnocení účinnosti a bezpečnosti injekce BAT4406F u pacientů s neuromyelitidou a onemocněním optické linie

This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study, to investigate the efficacy and safety of BAT4406F injection in patients with neuromyelitis optica lineage disease (NMOSD) who are positive for aquaporin 4 antibody (AQP4-IgG) .

Přehled studie

Detailní popis

This study was a phase II/III multicenter, randomized, double-blind, placebo-controlled study, which was divided into screening period (4 weeks) , randomized control period (RCP) , and open-label period (Olp)A total of 162 subjects were enrolled during the screening period and randomly assigned 2:1 to either the BAT4406F group or the placebo group after randomization on Day 1 of the RCP, subjects would receive BAT4406F (at a dose of 500mg) or placebo, intravenously, at D 1 and D 182, respectively.

If any of the following conditions occur, subjects can enter OLP from RCP: 1. Subjects who complete the 52-week RCP study without recurrence of NMOSD can enter Olp within 14 days after the end of the RCP study. 2. In the stage of RCP, NMOSD recurred. After rescue therapy, the patients with stable condition could enter OLP within 28 days after diagnosis. Subjects continued to participate in the RCP study if they were not identified by CEC as having a relapse upon examination. 3. When a protocol-defined first relapse event of 35 cases is observed, or when all 162 subjects have completed randomization and 12 months have elapsed since the first dose in the last of these subjects, or when recommended by the Independent Data Monitoring Committee (IDMC) , the RCP study should be stopped for enrolled subjects, and all enrolled subjects at the RCP stage should stop the RCP study within 14 days of entry into OLP, after which subjects will receive BAT4406F injection at the same dose as RCP, at d 1 of OLP. After termination of the RCP study with BAT4406F every 6 months, subjects were given the option of enrolling in the OLP study.

Typ studie

Intervenční

Zápis (Odhadovaný)

162

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Baotou, Čína
        • The First Affiliated Hospital of the Baotou Medical College of Inner Mongolia University of Science and Technology
      • Beijing, Čína
        • Beijing Hospital
      • Beijing, Čína
        • China-japan friendship Hospital
      • Beijing, Čína
        • The first hospital of Peking University
      • Changsha, Čína
        • The Central South University Xiang Ya Hospital
      • Changsha, Čína
        • Xiangya 2nd hospital of central south university
      • Chongqing, Čína
        • First affiliated hospital of chongqing medical university
      • Dalian, Čína
        • The first affiliated hospital of Dalian Medical University
      • Fuzhou, Čína
        • First affiliated hospital of fujian medical university
      • Guangzhou, Čína
        • The first hospital affiliated to sun yat-sen university
      • Guangzhou, Čína
        • The third hospital affiliated to sun yat-sen university
      • Guangzhou, Čína
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
      • Guangzhou, Čína
        • The first People's Hospital of Guangzhou
      • Hangzhou, Čína
        • People's Hospital of Zhejiang province
      • Hefei, Čína
        • Anhui Provincial Hospital
      • Hefei, Čína
        • Second Affiliated Hospital of Anhui Medical University
      • Jinan, Čína
        • Shandong University Qilu Hospital
      • Jingzhou, Čína
        • Jingzhou Central Hospital
      • Kunming, Čína
        • First Affiliated Hospital of the Kunming Medical University
      • Nanchang, Čína
        • Second Affiliated Hospital of Nanchang University
      • Nanchong, Čína
        • Affiliated Hospital of North Sichuan Medical College
      • Nanjing, Čína
        • Drum Tower Hospital affiliated to Medical College of Nanjing University
      • Nanjing, Čína
        • The Chinese people's liberation army general hospital in eastern theater
      • Nanjing, Čína
        • Southeast university affiliated zhongda hospital
      • Nantong, Čína
        • The first People's Hospital of Nantong
      • Qingdao, Čína
        • Qingdao municipal hospital
      • Shanghai, Čína
        • Mount Hua Hospital affiliated to Fudan University
      • Shanghai, Čína
        • Shuguang hospital affiliated to Shanghai University of Traditional Chinese medicine
      • Shanghai, Čína
        • Zhongshan hospital affiliated to Fudan University
      • Shenzhen, Čína
        • Shenzhen city people's hospital
      • Shijia Zhuang, Čína
        • Second Hebei Medical University Hospital
      • Shijiazhuang, Čína
        • The Third Hospital of Hebei Medical University
      • Suzhou, Čína
        • The Second Affiliated Hospital of Suzhou University
      • Suzhou, Čína
        • First Affiliated Hospital of Suzhou University
      • Taiyuan, Čína
        • The first hospital of shanxi medical university
      • Tianjin, Čína
        • Tianjin Medical University General Hospital
      • Wenzhou, Čína
        • The first hospital affiliated to wenzhou medical college
      • Wuhan, Čína
        • Tongji hospital affiliated to tongji medical college huazhong university of science and technology
      • Wuhan, Čína
        • Xiehe hospital affiliated to tongji medical college huazhong university of science and technology
      • Wuxi, Čína
        • Wuxi city people's hospital
      • Xi'an, Čína
        • Second Affiliated Hospital of the People's Liberation Army Air Force Military Medical University
      • Xi'an, Čína
        • Xi'an high-tech Hospital Co. , Ltd.
      • Xianyang, Čína
        • Yan 'an University Xianyang Hospital Co. , Ltd.
      • Zhengzhou, Čína
        • Henan province people's hospital
      • Zhenzhou, Čína
        • Zhengzhou university first affiliated hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 65 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Age greater than or equal to the age of 18 and less than or equal to 65 patients, gender not limited;
  2. Met the 2015 international NMO diagnostic panel (IPND) criteria for NMOSD, And AQP4-IGG positive patients
  3. Screening before 2 times at least 2 years experience with clinical records of relapse,or experienced at least 1 clinically documented recurrence within 1 year prior to screening
  4. For subjects who had a relapse before screening, symptoms needed to be stable for at least 4 weeks before randomization
  5. Into the group of former dosage of corticosteroids under 30 mg and prednisone equivalent,and the trial drug must be used within a month after the withdrawal of hormones
  6. The score of EDSS 7 or less
  7. Has the fertility of men and women must agree during treatment and 6 months after the last dose of using effective birth control method;
  8. Agreed to participate in trials, and books to sign the informed consent

Exclusion Criteria:

  1. CD19 + b-cell count below the lower limit of normal, b-cell-scavenger drugs used 6 months before baseline or within 5 half-lives of the drug, whichever is older (including but not limited to Rituximab, enalizumab, etc.) ;

  2. 6 months prior to the baseline used other monoclonal antibody therapy;Baseline used within five half-life before other biological preparation;

  3. Used it for 3 months prior to the baseline McCaw phenol ester, azathioprine and methotrexate;6 months prior to the baseline using cyclophosphamide;Baseline before five half-life

  4. Within a month before the filter used intravenous immunoglobulin (IVIG), plasma exchange (PE);

  5. Within 4 weeks before screening received vaccine or live attenuated;Within 2 weeks before the baseline received inactivated vaccine;Baseline received within 4 weeks before the new coronavirus vaccine

  6. In another clinical study and the baseline from the test drug treatment under three months or 5 half-life of the drug (the long time limit shall prevail);

  7. This test for monoclonal antibody has a history of allergies, known in drug allergy patients;Serious drug allergy or for two or over two kinds of food or drugs;

  8. 6 months prior to screening, except NMOSD need continuous oral or intravenous glucocorticoid dose > 20 mg/day of any more than 21 days

  9. Abnormal liver, kidney and bone marrow reserve

  10. HIV positive at HIV history or enrollment screening; History of hepatitis B Andor hepatitis C or Hepatitis B surface antigen (HBSAG) positivity at screening [ or Hepatitis B core antibody positive, hepatitis B surface antibody negative, Hepatitis B virus deoxynucleotides (HBV DNA) quantification exceeding normal range ] ; Or Hepatitis C virus (HCV) antibody positive [ with HCV-rna quantitation exceeding the normal range ] , Treponema pallidum antibody positive at the time of enrollment;

  11. Comply with any of the following subjects a latent or active TB infection related standards:

    1. Current or past people with active TB;
    2. In history and/or physical examination during filter tip physical signs or symptoms of active TB;
    3. Recent close contact with people with active TB;
    4. At the time of screening, the positive result of TB infected T cells was found. A test could be repeated if the subject's first tb-infected t-cell test result was inconclusive, and the patient was excluded from this study if the test result was inconclusive (or positive) again.
  12. Covid-19 infection was diagnosed with clinical symptoms or signs consistent with 2019 coronavirus (COVID-19) infection (eg, fever, dry cough, dyspnea, sore throat, and fatigue) within 4 weeks before screening or during screening, or upon appropriate laboratory testing (at the discretion of the investigator or in accordance with local regulations) . If COVID-19 infection is confirmed before screening, appropriate laboratory testing is required to confirm that the infection has been cured;

  13. Suffering from metabolic, hematological, renal, hepatic, pulmonary, neuroendocrine, cardiac, infectious, gastrointestinal or other autoimmune diseases, the researchers believe there is an unacceptable risk to patients, or it may affect NMOSD assessment;

  14. According to the researchers, there was a history of drug and alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 125 mL of wine) in the 12 months before screening;

  15. Subjects who are unable to undergo an MRI scan (for example, are allergic to Gd-containing MRI contrast media, have a pacemaker, defibrillator, or other metallic object with internal or external limitations to performing an MRI scan) ;

  16. Pregnant or lactating women, and screening or baseline pregnancy test positive female subjects;

  17. Researchers think that the other does not fit to participate in this study.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Trojnásobný

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Experimental group:BAT4406F

RCP:Intravenous infusion; Dosage:500mg/time; Time of administration:The drug was given at D 1 and D 182 respectively OLP:Intravenous infusion; Dosage:500mg/time; Time of administration: After D1 dosing, Every 6 months to 1 times

Intravenous infusion; Dosage:500mg/time

Aktivní komparátor: Control group:BAT4406F Placebos

RCP:Intravenous infusion; Dosage:500mg/time; Time of administration:The drug was given at D 1 and D 182 respectively OLP:Intravenous infusion; Dosage:500mg/time; Time of administration: After D1 dosing, Every 6 months to 1 times

Intravenous infusion; Dosage:500mg/time

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Pharmacodynamics
Časové okno: RCP: Day7, Day14, Day28, Day56, Day84, Day112, Day140, Day182, Day280, Day364. OLP:D7, D28, Day84, Day182, Day280, Day364. Week 40+26n (n=1, 2, 3.....) , Week 52+26n (n=1, 2, 3.....). And OLP maximum period for 3 years

The follow-up time point of peripheral blood before and after the analysis to the medicine CD19 + B lymphocytes proportion/count change

RCP: Day7, Day14, Day28, Day56, Day84, Day112, Day140, Day182, Day280, Day364. OLP:D7, D28, Day84, Day182, Day280, Day364. Week 40+26n (n=1, 2, 3.....) , Week 52+26n (n=1, 2, 3.....). And OLP maximum period for 3 years
Pharmacodynamics
Časové okno: RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years

Serum immunoglobulin (IgG and IgM) levels were measured.

RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years
Pharmacodynamics
Časové okno: RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years

AQP4-IgG levels were measured.

RCP:in Day84、Day182、Day280、Day364. OLP: in Day1、Day84、Day182、Day280、Day364 of every years.And OLP maximum period for 3 years
Pharmacokinetics(PK)
Časové okno: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Cmax

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Časové okno: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Tmax

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Časové okno: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Cmin

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Časové okno: Through study completion,up to 49 months. And OLP maximum period for 3 years.

AUC0-tau

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Časové okno: Through study completion,up to 49 months. And OLP maximum period for 3 years.

t1/2

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Časové okno: Through study completion,up to 49 months. And OLP maximum period for 3 years.

CL

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Pharmacokinetics(PK)
Časové okno: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Vd

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Immunogenicity evaluation
Časové okno: RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years

Resistant antibody positive rate (ADA)

RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years
Immunogenicity evaluation
Časové okno: RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years

The titers of Ada positive samples

RCP:in Day84、Day181、Day252、Day364. OLP: in Day84、Day181、Day252、Day364 of every years.And OLP maximum period for 3 years

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Vital signs
Časové okno: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal vital signs

Through study completion,up to 49 months. And OLP maximum period for 3 years.
physical examination
Časové okno: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal physical examination findings

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Laboratory tests
Časové okno: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal laboratory test results

Through study completion,up to 49 months. And OLP maximum period for 3 years.
electrocardiogram( ECG )
Časové okno: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with abnormal ECG readings

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Adverse events(AE)
Časové okno: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Adverse events (AE) is happening, is happening because of adverse events leading to withdrawal Adverse events associated with drugs The occurrence of Serious adverse events (SAE)

Through study completion,up to 49 months. And OLP maximum period for 3 years.
Injection site reactions
Časové okno: Through study completion,up to 49 months. And OLP maximum period for 3 years.

Number of participants with injection site reactions

Through study completion,up to 49 months. And OLP maximum period for 3 years.

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Xiangjun Chen, Doctor, Huashan Hospital
  • Vrchní vyšetřovatel: Chunfeng Liu, Doctor, Second Affiliated Hospital of Suzhou University
  • Vrchní vyšetřovatel: Qun Xue, Doctor, First Affiliated Hospital of Suzhou University
  • Vrchní vyšetřovatel: Yan Jiang, Doctor, Anhui Provincial Hospital
  • Vrchní vyšetřovatel: Yuying Zhao, Doctor, Shandong University Qilu Hospital
  • Vrchní vyšetřovatel: Li Guo, Doctor, Second Hebei Medical University Hospital
  • Vrchní vyšetřovatel: Meini Zhang, Doctor, The First Affiliated Hospital of Shanxi Medical University
  • Vrchní vyšetřovatel: Huan Yang, Doctor, The Central South University Xiang Ya Hospital
  • Vrchní vyšetřovatel: Daishi Tian, Doctor, Tongji hospital affiliated to Tongji Medical College
  • Vrchní vyšetřovatel: Yuming Xu, Doctor, The First Affiliated Hospital of Zhengzhou University
  • Vrchní vyšetřovatel: Jianglong Tu, Doctor, Second Affiliated Hospital of Nanchang University
  • Vrchní vyšetřovatel: Wei Qiu, Doctor, The third hospital affiliated to sun yat-sen university
  • Vrchní vyšetřovatel: Honghao Wang, Doctor, The First People's Hospital of Guangzhou
  • Vrchní vyšetřovatel: Xiaoling Luo, Doctor, Shenzhen city people's hospital
  • Vrchní vyšetřovatel: Aiyu Lin, Doctor, First Affiliated Hospital of Fujian Medical University
  • Vrchní vyšetřovatel: Chunming Xie, Doctor, China University Hospital of Southeast University
  • Vrchní vyšetřovatel: Xiang Li, Doctor, The first hospital affiliated to wenzhou medical college
  • Vrchní vyšetřovatel: Lan Tan, Doctor, Qingdao City Hospital
  • Vrchní vyšetřovatel: Fudong Shi, Doctor, Tianjin Medical University General Hospital
  • Vrchní vyšetřovatel: Jiewen Zhang, Doctor, Henan Provincial People's Hospital
  • Vrchní vyšetřovatel: Jing Ding, Doctor, Shanghai Zhongshan Hospital
  • Vrchní vyšetřovatel: Ping Chen, Doctor, Xianyang yanan university hospital co., LTD
  • Vrchní vyšetřovatel: Zunbo Li, Doctor, Xi'an high-tech Hospital Co. , Ltd.
  • Vrchní vyšetřovatel: Qihe Dai, Doctor, Jingzhou city central hospital
  • Vrchní vyšetřovatel: Dan Liu, Doctor, the first hospital of Baotou medicine college
  • Vrchní vyšetřovatel: Junyan Liu, Doctor, Hebei Medical University Third Hospital
  • Vrchní vyšetřovatel: Yiqi Wang, Doctor, Zhejiang Province People's Hospital
  • Vrchní vyšetřovatel: Bo Hu, Doctor, Xiehe hospital affiliated to tongji medical college
  • Vrchní vyšetřovatel: Yanbing Han, Doctor, First Affiliated Hospital of the Kunming Medical University
  • Vrchní vyšetřovatel: Feng Wang, Doctor, Wuxi city people's hospital
  • Vrchní vyšetřovatel: Zhanhua Liang, Doctor, The First Affiliated Hospital of Dalian Medical University
  • Vrchní vyšetřovatel: Weihe Zhang, Doctor, Sino-Japanese Friendship Hospital
  • Vrchní vyšetřovatel: Xiangyang Zhu, Doctor, Nantong First People's Hospital
  • Vrchní vyšetřovatel: Xinfeng Liu, Doctor, The Chinese people's liberation army general hospital in eastern theater
  • Vrchní vyšetřovatel: Weidong Pan, Doctor, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
  • Vrchní vyšetřovatel: Wei Lu, Doctor, The Central South University Xiang YA II hospital
  • Vrchní vyšetřovatel: Huiyu Feng, Doctor, The first hospital affiliated to sun yat-sen university
  • Vrchní vyšetřovatel: Yamei Tang, Doctor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • Vrchní vyšetřovatel: Juming Yu, Doctor, Affiliated Hospital of North Sichuan Medical College
  • Vrchní vyšetřovatel: Jun Guo, Doctor, The Second Affiliated Hospital of the PLA Air Force Military Medical University
  • Vrchní vyšetřovatel: Yanghua Tian, Doctor, The Second Hospital of Anhui Medical University
  • Vrchní vyšetřovatel: Feng Gao, Doctor, The first hospital of Peking University
  • Vrchní vyšetřovatel: Yun Xu, Doctor, Drum tower hospital affiliated to nanjing university school of medicine

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

1. srpna 2023

Primární dokončení (Odhadovaný)

31. prosince 2027

Dokončení studie (Odhadovaný)

31. prosince 2027

Termíny zápisu do studia

První předloženo

31. července 2023

První předloženo, které splnilo kritéria kontroly kvality

12. září 2023

První zveřejněno (Aktuální)

21. září 2023

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

2. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

29. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • BAT-4406F-002-CR

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit